Initially developed by Novo Nordisk in the 1990s, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selective agonist of the GHS-R1a receptor (ghrelin receptor), responsible for stimulating pulsatile growth hormone secretion without the cross-side effects characteristic of non-selective GHRPs
Injectable semaglutide, particularly Wegovy at 2.4 mg weekly, produces significantly greater weight loss than oral semaglutide
ActRII not only exists in muscle cells, but also plays an important role in fat cells
Perry VH, Nicoll JA, Holmes C
Policy Cleveland Clinic hepatologist and senior author Dian Chiang, MD, MPH, calls the findings a critical piece of information that could help guide treatment decisions
Cosmetic/topical forms are cash-pay